Evogene cancer combination therapy meets safety goal in early trial
Evogene (NASDAQ:EVGN) announced that a first-in-human Phase 1 clinical trial evaluating its experimental microbiome-based oncology therapy, BMC128, successfully met its primary safety endpoint when administered in combination with the immunotherapy drug Nivolumab.






_1412462_640x360_2502167107518-640x360.webp&w=3840&q=75)



_1412453_640x360_2502165571722-640x360.webp&w=3840&q=75)
